Back to results

TerminatedPhase 3

GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes

NCT00300105

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Hasselt, Belgium

+41 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2005-10
Enrollment: 400 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (42)

Research SiteHasselt, Belgium
Research SiteLiège, Belgium
Research SiteSint-Gillis-Waas, Belgium
Research SiteSteenokkerzeel, Belgium
Research SiteShatin, Hong Kong
Research SiteBalatonfüred, Hungary
Research SiteBudapest, Hungary
Research SiteKaposvár, Hungary
Research SiteKecskemét, Hungary
Research SiteSzékesfehérvár, Hungary
Research SiteGubbio, Italy
Research SiteMilan, Italy
Research SitePerugia, Italy
Research SitePiacenza, Italy
Research SiteReggio Emilia, Italy
Research SiteUdine, Italy
Research SiteKubang Kerian, Kelantan, Malaysia
Research SiteKuala Lumpur, Malaysia
Research SiteMakati City, Philippines
Research SiteManila, Philippines
Research SitePasig, Philippines
Research SiteKrakow, Poland
Research SiteLublin, Poland
Research SitePłock, Poland
Research SiteTorun, Poland
Research SiteTychy, Poland
Research SiteWarsaw, Poland
Research Site£ód?, Poland
Research SiteBanská Bystrica, Slovakia
Research SiteBratislava, Slovakia
Research SiteIlava, Slovakia
Research SiteKošice, Slovakia
Research SiteKysucké Nové Mesto, Slovakia
Research SiteLučenec, Slovakia
Research SiteĽubochňa, Slovakia
Research SiteNitra, Slovakia
Research SitePrešov, Slovakia
Research SiteTrnava, Slovakia
Research SiteJohannesburg, Gauteng, South Africa
Research SiteCape Town, South Africa
Research SiteDurban, South Africa
Research SiteBangkok, Thailand

GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes — TrialFind